Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00084279
Status:
COMPLETED
Last Update Posted:
2009-07-03
First Post:
2004-06-09
Brief Title:
CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C Nonresponders
Sponsor:
InterMune
Organization:
InterMune
Study Overview
Official Title:
Safety and Tolerability of Consensus Interferon-Alpha CIFN Plus Interferon Gamma-1b IFN-γ 1b With or Without Ribavirin RBV in the Treatment of Patients With Chronic Hepatitis C Who Are Non-Responders to PEG-IFN-a 2a or 2b Plus RBV
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who are non-responders to PEG-IFN-a 2a or PEG-IFN-a 2b plus ribavirin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None